Approval · Notice of Compliance 15973 · 2014
VOLIBRIS: Notice of Compliance 15973
Issued August 18, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 15973
- Date
- August 18, 2014
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Remove a statement in the indication and clinical use section of the product monograph
- Therapeutic class
- Endothelin receptor antagonist
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VOLIBRIS | Not yet assigned | — |
Medicinal ingredients
- AMBRISENTAN 5 MG per TAB
- AMBRISENTAN 10 MG per TAB